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Abstract
Hereditary spastic paraplegias (HSPs) comprise a group of neurodegenerative disorders that are characterized by
progressive spasticity of the lower extremities, due to axonal degeneration in the corticospinal motor tracts. HSPs are
genetically heterogeneous and show autosomal dominant inheritance in ,70–80% of cases, with additional cases being
recessive or X-linked. The most common type of HSP is SPG4 with mutations in the SPAST gene, encoding spastin, which
occurs in 40% of dominantly inherited cases and in ,10% of sporadic cases. Both loss-of-function and dominant-negative
mutation mechanisms have been described for SPG4, suggesting that precise or stoichiometric levels of spastin are
necessary for biological function. Therefore, we hypothesized that regulatory mechanisms controlling expression of SPAST
are important determinants of spastin biology, and if altered, could contribute to the development and progression of the
disease. To examine the transcriptional and post-transcriptional regulation of SPAST, we used molecular phylogenetic
methods to identify conserved sequences for putative transcription factor binding sites and miRNA targeting motifs in the
SPAST promoter and 39-UTR, respectively. By a variety of molecular methods, we demonstrate that SPAST transcription is
positively regulated by NRF1 and SOX11. Furthermore, we show that miR-96 and miR-182 negatively regulate SPAST by
effects on mRNA stability and protein level. These transcriptional and miRNA regulatory mechanisms provide new functional
targets for mutation screening and therapeutic targeting in HSP.
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Introduction
Hereditary spastic paraplegias (HSPs) are a group of genetically
heterogeneous neurodegenerative disorders that are characterized
by progressive symmetric spasticity of lower extremities [1–5].
Neuropathological studies have shown that HSP patients have
axonal degeneration of the corticospinal or pyramidal motor and
sensory tracts that control the lower extremities [3–4,6]. HSP may
be accompanied by muscle weakness, increased stiffness, hyperre-
flexia, extensor plantar responses, bladder disturbances, and
vibratory sense impairment [2,4]. HSPs are clinically classified
as ‘pure’ when they occur with the above features in isolation and
‘complicated’ when they are associated with additional neurolog-
ical disorders such as mental retardation, amyotrophy, epilepsy,
ataxia, deafness, or optic neuropathy [2,4].
HSPs are genetically heterogeneous with many genes involved
in their etiology. Dominant inheritance accounts for ,70% of
HSP, although the mode of inheritance can also be autosomal
recessive, X-linked, or sporadic with no familial pattern [2–3,7].
Classification of HSPs is based on their specific chromosomal
gene/locus as ‘‘SPG’’ (spastic gait) followed by a progressive
number. To date, 48 chromosomal loci have been linked to
pathogenesis, although for about half of these the etiological gene
remains unidentified [2–3,5,7]. The most common form of HSP,
SPG4, results from various types of mutations in SPAST, which
occur in 40% of the dominantly inherited cases [3–4,7–8]. These
mutations include nonsense, missense, and splice mutations that
affect the coding sequence (http://www.hgmd.cf.ac.uk/ac/gene.
php?gene = SPAST) [9–13] as well as deletions or duplications of
coding exons [8,10–12,14]. Mutations in other genes also result in
autosomal dominant HSP, including REEP1 (SPG31), ATL1
(SPG3A), KIF5A (SPG10), HSPD1 (SPG13), NIPA1 (SPG6),
KIAA1096 (SPG8), BSCL2 (SPG17), and SLC33A1 (SPG42), but
the frequency of such occurrences is minor in comparison to
SPAST mutations [10,13,15–21].
SPAST encodes spastin, which is a member of the AAA
(ATPases associated with a variety of cellular activities) protein
family [5,22–23]. Spastin possesses microtubule-severing ability,
and contributes to membrane modeling, intracellular and axonal
transport of vesicles [1,3,5,7]. It has been suggested that
mutations in SPAST lead to disease pathogenesis by a haploin-
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sufficiency mechanism [14,24–25]. Alternatively, at least some
SPG4 cases appear to involve a dominant-negative mutation
mechanism [26–27]. Combined, the evidence suggests that
precise or stoichiometric levels of spastin are necessary for
biological function, which may not be surprising given that
spastin forms a hexameric ring with pore loops that bind and tug
the tubulin C-terminal tails to disrupt tubulin polymeric
interactions and sever microtubules [28–30]. Therefore, we
hypothesize that alterations in the production level of spastin
could contribute to the development or progression of disease. In
order to address how spastin is produced, we examined
regulatory mechanisms involved in the expression of SPAST in
eutherian mammals, including human. We demonstrate that the
transcription factors (TFs) NRF1 and SOX11 as well as the
microRNAs (miRNAs) miR-182 and miR-96 are major factors
involved in the regulation of SPAST. These findings provide
a foundation for understanding regulation of spastin expression,
identify new target sequences for mutation screening at the SPG4
locus, and suggest novel approaches to consider for therapeutic
approaches in dominantly inherited spastic paraplegia.
Results
Previous studies have shown that SPAST has numerous
transcriptional start sites (TSS) that define the first exon, although
two major alternative TSS for SPAST can be delineated (Fig. 1A)
[31]. Interestingly, the region between the two TSS has partial
promoter activity [31], while the 179-bp region 59 of the first TSS
has the highest levels of SPAST promoter activity [31,32].
However, the TFs regulating SPAST promoter activity have not
been previously defined, particularly upstream of the 59-most TSS.
To examine the transcriptional as well as post-transcriptional
regulation of SPAST, we used molecular phylogenetic methods
[33–34] to identify conserved sequences of putative TF binding
sites and miRNA targeting motifs in the SPAST promoter and 39-
UTR, respectively. Subsequently, we used a variety of molecular
experimental methods to confirm and extend the predictions from
the phylogenetic approach.
Evolutionary Conserved cis-binding Motifs in the SPAST
Promoter
Using bioinformatics analysis, the non-coding region upstream
of the two TSS for SPAST was found to be rather poorly conserved
in 21 mammals with sufficient sequence coverage for full analysis,
without a single motif of $6-nt as expected for a TF binding site
(Fig. 1A,B; Fig. S1A,B,C). Nevertheless, several patches of
increased conservation corresponded to motifs identical to the
consensus binding sites for three TFs. The most highly conserved
motif, 59-CAACAAAGA-39 (Fig. 1B; Fig. S1A,C) corresponds to
a consensus binding motif for SOX11 and SOX4 [35–36],
members of the SOX-C family of TFs [37]. This putative TF
binding site is identical in 19 of 20 eutherian mammals (Fig. 1B)
and in two marsupials, the South American opossum (Fig. S1C)
and tammar wallaby (data not shown), but has been replaced in
the elephant (Fig. S1B). Flanking either side of the putative
SOX11/SOX4 motif were 1–3 copies of a related sequence in
different mammals (Fig. 1A,B; Fig. S1A,B,C), each matching the
binding motif 59-yGCGCAnGCGCr-39 that is specific for nuclear
respiratory factor-1 (NRF1) [38–39]. The NRF1 consensus is both
a palindrome and repeating pyrimidine (y)-purine (r) sequence,
where a maximum of one mismatch in one GCGC motif is
allowed to maintain binding affinity [39–40], with the 39-most
motif in the SPAST promoter a perfect match to the NRF1
consensus. Interestingly, there are four NRF1 motifs in the
elephant SPAST promoter with 3 of these identical to the
consensus and derived by 18-nt and 29-nt duplications that
replace the putative SOX11/SOX4 motif (Fig. S1B). Finally,
although not generally conserved in the same position in all
species, there are up to 6 potential binding sites in each species
that match the GC-rich consensus for Sp1, typically found in
CpG-rich mammalian promoters [41]. Taken together, the
phylogenetic analysis suggests that NRF1, SOX11, and Sp1 may
contribute to SPAST transcriptional regulation in mammals.
NRF1 Positively Regulates Transcription of SPAST
To determine if NRF1 regulates the expression of SPAST, we
sought to first show that NRF1 physically binds to the SPAST
promoter. Using chromatin immunoprecipitation (ChIP) assays,
we found that NRF1 binds specifically and robustly to the SPAST
promoter in human SK-N-SH cells (Fig. 2A) and in murine
Neuro2a cells (Fig. 2B). Independently, these data have been
validated by ENCODE genome-wide ChIP studies that also
demonstrates NRF1 binding to the SPAST promoter region
(http://genome.ucsc.edu/cgi-bin/hgTracks). To confirm that
NRF1 not only binds the SPAST promoter but also plays a role
in its expression, we determined the effect on SPAST expression
resulting from reduction of NRF1 levels by targeting NRF1 mRNA
with a specific siRNA. A NRF1 shRNA expression vector
(pSUPER-NRF1) [42] transfected into SK-N-SH cells significantly
reduced NRF1 and SPAST transcript levels to,20% and ,60% of
mRNA levels measured in mock-transfected control cells, re-
spectively (Fig. 3).
To further validate the role of NRF1 in SPAST expression, we
generated a SPAST-promoter-luciferase reporter construct by
ligating a 304-bp fragment of the SPAST promoter (-197 to+107
relative to the 59-TSS) and containing all conserved TF motifs into
the pGL3e luciferase reporter vector (Fig. 4A). This full-length
SPAST-promoter construct was then co-transfected into SK-N-SH
cells with each of three different pSUPER-shRNA vectors.
Compared to control cells expressing an unrelated siRNA [42],
which have a high level of luciferase activity, siRNA specially
targeting the luc-coding sequence significantly decreased luciferase
levels by ,66% (Fig. 4B); retention of some luciferase activity is
likely due to protein stability or incomplete mRNA knockdown. In
contrast, siRNA specifically targeting NRF1 virtually abolished
luciferase activity with only basal levels detected (Fig. 4B).
Combined, these results show that NRF1 is an essential positive
regulator of SPAST transcription.
SOX11 Activates SPAST Transcription
To determine if the putative SOX11 binding site is involved in
transcriptional regulation of SPAST, we engineered a set of nested
deletions in the full-length SPAST-promoter-luciferase reporter
construct, which contains a binding site for NRF1 and putative
binding motifs for Sp1 and SOX11 (Fig. 5A, left). Each construct
was transfected into human Flp-In-293 cells. Compared to the full-
length SPAST-promoter with robust transcriptional activation of the
luciferase reporter (almost 40-fold over the pGL3b vector control),
deletion of the 59-most Sp1 motif and an NRF1-like motif (the latter
expected to have low affinity in human, due to two changes from the
NRF1 consensus [40]) led to a statistically significant ,20%
reduction in luciferase activity (Fig. 5A, right). An additional
deletion that specifically removed 37-nt including only the putative
SOX11 binding motif further significantly reduced promoter-driven
luciferase activity by another ,23% (Fig. 5A, right). To establish
whether SOX11 binding is responsible for the latter positively-
acting cis-element, we used co-transfection of a SOX11 expression
vector [43] to over-express SOX11 along with the same set of three
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SPAST-promoter-luciferase reporters (Fig. 5B, left). Indeed,
SOX11 over-expression significantly increased luciferase activity
for the two SPAST-promoter reporter vectors with the putative
SOX11 binding motif but not for the reporter construct that lacked
this site (Fig. 5B, right). These results indicate that SOX11 acts as
a positively-acting TF for SPAST expression.
Figure 1. Transcriptional regulation of the SPAST gene encoding spastin (SPG4). A) Cartoon showing the human SPAST promoter structure
with cis-elements representing putative transcription factor (TF) binding sites for NRF1, SOX11, and Sp1. As is typical of CpG-promoters, transcription
start sites (TSS) are spread over a large region in exon 1, with two major TSS positions indicated by arrows [31]. There are two alternative translational
initiation codons for spastin 68 and 60 kDa polypeptide isoforms, respectively [31]. B) Multi-sequence alignment of conserved TF cis-elements in
representative mammalian species. Sequences were aligned using ClustalW 2.1 and manually adjusted as needed for maximum parsimony.
Evolutionarily conserved TF motifs are indicated; *, nucleotide positions conserved in all 19 species; ‘, nucleotide positions conserved in 17/19
species; yellow shading, highly conserved SOX11 motif; red, NRF1 motifs; purple, Sp1 motifs. The NRF1 and SOX11 motifs are highly conserved, but
only one Sp1 motif near the 59 TSS is conserved in mammals. Extended alignments of the complete promoter region into exon 1 and including the
first translational start codon are shown in Fig. S1.
doi:10.1371/journal.pone.0036505.g001
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NRF1 and SOX11 Increase Endogenous Levels of
SPAST mRNA
To validate that NRF1 and SOX11 can positively regulate
SPAST expression in a native chromatin configuration and cellular
milieu, we investigated whether these TFs affect endogenous levels
of SPAST mRNA. To accomplish this we transfected Flp-In-293
cells with SOX11 (pSOX11-CMV) and NRF1 (pNRF1-VP16)
expression vectors, as well as an empty plasmid (pGL3b)
transfection control. The VP16 transactivation domain fused to
NRF1 increases the upregulation of NRF1-target genes by 4-fold
compared to NRF1 alone but does not change the specificity [44].
SPAST mRNA expression levels were assayed by quantitative
qRT-PCR, normalizing 1) to GAPDH mRNA level, a gene that is
not regulated by NRF1 or SOX11, and 2) to the SPAST mRNA
level in the pGL3b transfection control. Over-expression of
SOX11 or NRF1 led to a significant increase in level of
endogenous SPAST mRNA (Fig. 6).
A Minimal Role for Elk1 in Regulation of SPAST
A recent report suggested that another TF, Elk1, repressed
transcriptional activity through a binding site located in the 59 SPAST
promoter [32]. However, the putative Elk1 site [32] is poorly
conserved in mammals, other than for simian primates (Fig. S1A).
We tested the potential transcriptional activity of a 182-bp segment
upstream of the full-length SPAST promoter, lacking conserved
sequence elements but containing the putative Elk1 site, using
luciferase reporter assays in Flp-In-293 cells. The 182-bp fragment
induced a slight but significant increase in luciferase activity over the
promoterless control vector whereas when placed upstream of the
highly active, full-length SPAST promoter there was a slight but non-
significant decrease in luciferase activity (Fig. S2). These results
suggest that Elk1 has a limited role in transcriptional regulation of
SPAST.
Evolutionary Conserved cis-targeting Motifs in the
SPAST 39-UTR
To more fully understand SPAST regulation, beyond
transcriptional controls, it is necessary to explore mechanisms
of post-transcriptional regulation of SPAST by miRNAs. Three
criteria were assessed to identify candidate miRNA regulators,
including 1) presence of optimal 7mer or 8mer seeds [45] and
Figure 2. NRF1 chromatin immunoprecipitation (ChIP) assays. NRF1 interacts with the SPAST promoter in A) human SK-N-SH cells, and B)
murine Neuro2a cells, by ChIP assay. The SNURF-SNRPN enhancer for human and Snurf-Snrpn promoter for mouse are positive controls for cis-
elements known to be bound by NRF1 [89]. Chromatin was immunoprecipitated with anti-NRF1 antibodies, and the promoter regions were assessed
by PCR. Controls are no antibody (no Ab) and total input DNA (TI) for ChIP, and a water control (H2O) for PCR.
doi:10.1371/journal.pone.0036505.g002
Figure 3. siRNA targeting NRF1 mRNA knocks down SPAST
mRNA expression. SK-N-SH cells were transfected with a pSUPER-
NRF1 shRNA expression vector or mock transfected, with qualitative
analysis of gene expression including a negative control (GAPDH). The
quantitative band intensities for the ‘‘siRNA’’ and ‘‘mock’’ transfection
samples were compared and the ratio is listed to the right of the gel
images. The GAPDH mRNA level is unaffected by siRNA targeting NRF1,
whereas the mRNA levels for NRF1 and SPAST are reduced by the siRNA
treatment. The experiment was repeated three times with equivalent
results to the representative results shown here.
doi:10.1371/journal.pone.0036505.g003
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2) conserved seeds for miRNA targeting within the SPAST 39-
UTR, using the TargetScan database, and 3) evolutionary
conservation of optimal seeds amongst animals with sequenced
genomes, using the BLAST algorithm. Five sets of miRNA
seeds match these criteria: miR-96, miR-200bc/429, miR-132/
212, miR-30abcde/384, and miR-29abc (Table S1). However,
only the SPAST 39-UTR seed match for miR-96 was conserved
in all mammals (eutherians and marsupials) and in sequenced
tetrapod genomes (see below; Table S1). We therefore focused
on experimental assessment of the role of miR-96 in SPAST
regulation.
Post-transcriptional Regulation of SPAST by miR-96/2182
miRNAs
Bioinformatic analysis of the human SPAST 39-UTR sequence
predict two miR-96 sites, one with an optimal 8mer seed match
(ie., 5-UUUGGCAC-39, nucleotides 1–8) and an adjacent one
located 36 to 61-nt 59 with a potential 7mer-A1 type seed
interaction through nucleotides 1–7 of miR-96 (Fig. 7A,B). In
addition, miR-182, a related miRNA localized in the same
polycistronic cluster [46] is also predicted to potentially target
SPAST via 7mer-A1 type seed interactions at the same positions
(Fig. 7A,B). Although a recent study identified three unrelated
mRNAs targeted and downregulated by miR-96 via 8mer sites
but not affected by miR-182 through 7mer-A1 sites [47], we
found this does not apply to SPAST perhaps due to differences in
cell lines, experimental conditions, or the paired target sites in
SPAST. This finding clearly indicates the importance of
experimental verification of in silico predictions. The optimal
(8mer) miR-96 target site is conserved in the SPAST 39-UTR of
all 38 mammalian species with SPAST sequences, including two
marsupials (opossum and Tasmanian devil), whereas the second
(59) potential miR-96 site is conserved in only 27 of these species
(Fig. 7C); nevertheless, a second miR-96 (7mer-A1) site is found
within 108 to 157-nt 39 of the optimal miR-96 site in 5 of 10
mammals lacking the 59 site (data not shown). Remarkably, the
miR-96 optimal seed is present in the same relative position in
the SPAST 39-UTR in all tetrapods with sequenced genomes,
despite otherwise little homology within the 39-UTR across
tetrapod species (Fig. 7D). Due to the shared seed motif with
miR-96, for position 1–7, miR-182 is likewise predicted to target
the SPAST 39-UTR across tetrapods.
To experimentally demonstrate involvement of miR-96 and
miR-182 in the post-transcriptional regulation of endogenous
Figure 4. siRNA targeting NRF1 mRNA ablates SPAST promoter function. A) Cartoon showing the structure of the pGL3e-SPAST-promoter-
luciferase vector, and the inhibitory mechanisms of siRNA action. Symbols are as for Fig. 1A. B) The plasmid pGL3e-SPAST-promoter was co-
transfected into SK-N-SH cells with pSUPER shRNA vectors that target either NRF1, luciferase, or negative control (Arl2). *, P,0.05.
doi:10.1371/journal.pone.0036505.g004
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SPAST mRNA and/or spastin protein levels, we transfected Flp-
In-293 cells with Pre-miRNA oligonucleotides which are then
processed in the cytoplasm to the mature miRNAs. Over-
expression of miR-96 or miR-182 resulted in statistically
significant 45% and 57% decreases in SPAST transcript levels,
respectively (Fig. 8A). By western blotting, over-expression of
miR-96 or miR-182 reduced spastin protein to almost undetect-
able levels (Fig. 8B). We conclude that the related miR-96 and
miR-182 family of miRNAs provide strong regulation of spastin
synthesis in human neural cells and affect both mRNA and protein
levels, and that this mechanism likely extends across all tetrapod
organisms.
A Novel miRNA Regulatory Mechanism for SPAST
in Primates
The human SPAST 39-UTR is unusual in comparison to non-
primate animals in having an Alu repetitive element insertion in
antisense orientation, flanked by an 18-nt target site duplication
typical of retrotransposition by the L1 pathway (Fig. 7A; Fig.
S3C,D). Intriguingly, a subset of human miRNAs target
sequences within Alu elements in the sense or antisense
orientation of 39-UTRs [48]. Among those that target areas
of antisense Alu elements with minimal sequence variation [48],
we focused on the potential targeting of the SPAST 39-UTR Alu
sequence by the miR-25/32/92ab/363/367 set of miRNAs
(Fig. 7A; Fig. S3A,B). Each miRNA in this set would target
the SPAST 39-UTR through an optimal seed of the 7mer-m8 or
8mer type (Fig. S3B). We focused on experimental assessment
of miR-367, on the basis of the most extensive potential to pair
with its potential target (Fig. S3A,B), although in vivo any of the
other miRNAs in this set (miR-25/32/92ab/363) could be
involved in SPAST regulation. The putative miR-367 target site
in the SPAST 39-UTR is present only in catarrhine primates
(Fig. S3C,E) and correlates with the presence of the Alu
insertion (Fig. S3D,E). Over-expression of miR-367 by trans-
fection of Flp-In-293 cells with Pre-miR-367 resulted in
a significant 46% decrease in SPAST transcript level (Fig. 8A),
confirming that miR-367 and/or miRNAs sharing the same
seed can regulate SPAST expression.
Figure 5. Regulation of the human SPAST promoter by SOX11. A) Luciferase reporter assays with the human SPAST promoter. The plasmid
pGL3b-SPAST-promoter-Luc (third row) and two deletion derivatives (depicted in the panel on the left) were transfected into Flp-in293 cells and
normalized to cells transfected with the pGL3b vector (fourth row). *, P,0.05. B) Over-expression of SOX11 upregulates SPAST promoter-reporter
constructs having a SOX11 binding site. Flp-In-293 cells were transfected with SPAST-promoter-luciferase reporter constructs both with (blue) and
without (red) the SOX11 expression vector. *, P,0.05; **, P,0.001; ***, P,0.0001, and n.s., not statistically significant. Symbols in A and B are as for
Fig. 1A.
doi:10.1371/journal.pone.0036505.g005
Regulation of Spastic Paraplegia Gene 4 Expression
PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e36505
Discussion
Many biochemical processes contribute to axonal function
within the corticospinal tracts, including mitochondrial, endoplas-
mic reticulum (ER)-shaping, endosomal trafficking, and microtu-
bule stability, each affecting anterograde and retrograde axonal
transport [5,7,30]. As the longest axons in the body, the
corticospinal axons are exquisitely sensitive during human lifespan
to mutations in a variety of genes that affect the levels of molecules
involved in these functions. This can account for the genetic
heterogeneity in HSP [3,5,7], although one locus (SPG4) accounts
for the largest proportion of this genetic load [2,10,13]. Based on
the genetic characteristics of SPG4, with dominant inheritance
and loss of function and/or dominant-negative mechanisms as well
as the observed sensitivity of neural cells to modulation of spastin
levels [25], we sought to determine the transcriptional and post-
transcriptional mechanisms that control in vivo production of
spastin. By identification of evolutionarily conserved, functional
cis-elements in the promoter and 39-UTR of SPAST, we have
shown that the TFs NRF1 and SOX11 as well as the miRNAs
miR-182 and miR-96 play major roles in regulation of spastin
levels in neural cells. Together, these findings have implications for
understanding regulation of corticospinal neuronal functions, for
molecular diagnostic studies in HSP, and for potential therapeutic
approaches in neurodegenerative diseases such as HSP.
Transcriptional Regulatory Mechanisms for SPAST
Based on evolutionary conservation and molecular studies, we
have shown that NRF1 and SOX11 are the major TFs involved in
positive regulation of the mammalian SPAST promoter. In
addition, the presence of multiple, mostly non-conserved putative
Sp1 motifs [this study] in the region between the two major TSS
suggests that Sp1 contributes to SPAST regulation [31]. Our
analysis was limited to promoter regulation of SPAST expression
using in vitro cell models. Future studies will assess SPAST
regulation in vivo and determine if more distant elements such as
enhancers, repressors, or boundary elements contribute to SPAST
regulation.
SOX11 is part of the SOX-C family and is closely related to
SOX4 [37], with both TFs sharing cis-binding site preferences
[35–36] and overlapping expression patterns [37]. During
neural development, Sox11 and Sox4 are required for neural
cell survival but not for lineage specification or differentiation
[49]. Both are required for survival of neurons in the
developing spinal cord [50]. Sox11 has been shown to be
required for survival of sensory neurons [51] whereas in
sympathetic ganglia, Sox11 is expressed first and required for
proliferation of specific cell types with Sox4 appearing later and
required for cell survival [52]. Thus, SOX4 also likely regulates
the SPAST promoter, as we have shown for SOX11, and both
SOX11 and SOX4 may contribute to developmental regulation
of SPAST gene expression. HMG factors, including SOX11 and
SOX4, can bend DNA structures and lead to unwinding or
opening of chromatin [53]. Based on these functional properties,
we hypothesize that during development SOX11/SOX4 bind
the SPAST promoter to open chromatin and provide access to
other key TFs such as NRF1 that enhance transcriptional
activation of SPAST.
The SOX11 binding site in the SPAST promoter is highly
conserved in marsupials and eutherian (placental) mammals with
sequenced genomes. Surprisingly, a single sequenced eutherian
mammal, the elephant, has lost the SOX11 site which has been
replaced by four putative NRF1 binding motifs as a consequence
of local DNA duplications. The clustered NRF1 sites in the
elephant SPAST promoter are similar in structure to cis-elements
that form enhancer-like elements [54] and suggest cooperative
binding with higher levels of transcriptional activation. It is
tempting to speculate that this structural arrangement of the
SPAST promoter in the elephant leads to higher expression levels
in the motor cortex and may be associated with greater demands
for spastin activity in microtubule severing and/or ER-membrane
Figure 6. Over-expression of SOX11 and NRF1 upregulates endogenous SPAST expression. Cells were transfected with SOX11 or NRF1
expression vectors and compared to cells transfected with the transfection control (pGL3b). By qRT-PCR, with normalization to GAPDH mRNA levels
and to the transfection control, the levels of NRF1 and SOX11mRNA were increased 182628-fold and 2,9256241-fold on transfection with NRF1-VP16
and CMV1-SOX11, respectively (data not shown). Similarly, by qRT-PCR analysis, SPAST transcript levels are significantly increased by over-expression
of SOX11 and NRF1. These data represent the average of three biological replicates each done in triplicate. *, P,0.05.
doi:10.1371/journal.pone.0036505.g006
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Figure 7. Prediction of several conserved seed motifs for miRNA targets in the SPAST 39-UTR. A) Cartoon of the SPAST mRNA showing
positions of the coding sequence (green), polyA site (red), Alu repetitive element (gray) with target site duplication (black triangles), and miRNA
target sites (purple) analyzed in this study. B) Base-pairing of Homo sapiens (hsa) miR-96 and miR-182 miRNAs with the SPAST 39-UTR. The optimal
seed motifs (red or brown) for targeting by the miRNAs are at position 511–517 (#1) and 462–467 (#2), respectively, of the SPAST 39-UTR. C)
Evolutionary conservation of the miR-96 target site in the SPAST 39-UTR of mammals. The optimal target for the miR-96 seed (+2 to+8) is shown in
blue, an optimal miR-182 seed in green, and other nucleotides that can base pair with miR-96 are in gray. Sequences conserved in all 38 species are
Regulation of Spastic Paraplegia Gene 4 Expression
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modeling within the extremely long corticospinal tracts and/or
large brain of this species [55].
The close apposition of the SOX11 and NRF1 sites in the
SPAST promoter suggests that these TFs may interact with each
other. Many SOX factors interact with b-catenin and/or TCF (T
cell factor) to negatively or positively regulate the canonical Wnt
signaling pathway during embryogenesis and neurogenesis [56].
Both SOX11 and SOX4 activate Wnt signaling, and SOX4 binds
to both b-catenin and TCF [56]. Intriguingly, recent studies have
shown that the Drosophila ortholog of NRF1, Erect Wing (EWG),
interacts with an Armadillo/b-catenin-TCF complex at specific
chromatin sites and promotes Wnt/Wingless signaling in neurons
and flight muscle development [57]. Consistent with roles in
a common pathway, neurite outgrowth is induced by Wnt
signaling [58–61], SOX11 [43,51,62], NRF1 [63], and spastin
[25,64]. Furthermore, Wnt signaling is involved in guidance of
corticospinal axons that descend from the motor cortex and cross
the midline into and down the spinal cord [59]. Over-expression of
b-catenin decreases microtubule stability [65], consistent with
a role in axon growth, branching, and synaptic connections [66–
67]. Therefore, we hypothesize that the canonical Wnt pathway
acts via b-catenin co-activation of SOX11/SOX4 and/or NRF1
to regulate SPAST expression.
Post-transcriptional Regulation of SPAST by miRNAs
In this work, we have shown that miR-96 and miR-182
negatively regulate mRNA and protein levels of spastin, with the
target sites in the SPAST 39-UTR conserved in all sequenced
tetrapod species. Importantly, while miR-96 and miR-182 were
previously regarded as specific for sensory neurons [46,68], recent
studies in rodents show higher levels of these two miRNAs in
frontal cortex compared to hippocampus [69] and in motor
neurons compared to neural stem cells in embryonic spinal cord
[70]. Further work is needed to determine whether miR-96/2182
indicated by *, and sequences conserved in 35 of 38 (90%) species by ‘. D) Evolutionary conservation of the miR-96 target site in the SPAST 39-UTR of
tetrapods. Footnotes: a Distance in nucleotides from stop codon to the first position in the target site for the miR-96 seed. b The optimal target for the
miR-96 seed (+2 to+8) is shown in blue, other nucleotides that can base pair with miR-96 are in gray. c This distance corresponds to a manually
corrected sequence, to overcome a poor sequence assembly in the database version.
doi:10.1371/journal.pone.0036505.g007
Figure 8. Post-transcriptional regulation of SPAST. A) QRT-PCR data showing that miR-182, miR-96, and miR-367 reduce SPAST transcript levels
in Flp-In-293 cells. These data represent the average of three biological replicates each done in triplicate. **, P,0.001. B) Western blot analysis of
spastin and GAPDH protein expression in Flp-In-293 cells transfected with miR-96, miR-182, and the negative (neg) control (see Materials and
Methods).
doi:10.1371/journal.pone.0036505.g008
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down-regulate SPAST levels via target mRNA stability, as with the
majority of miRNAs [45,71–72] or whether they can also act
through translational regulation. Intriguingly, our data show that
another miRNA, miR-367, can also regulate SPAST mRNA levels
to a degree similar to miR-96 or miR-182, yet the miR-367/25/
32/92ab/363 target site in the SPAST 39-UTR only arose in the
catarrhine branch of primate evolution coincident with insertion of
an Alu repetitive element. This gain of novel miRNA regulation
targeting SPAST correlates with evolutionary changes in anatomy
and motor function of the motor cortex and corticospinal tract
[73]. Future studies will examine the functional contribution in
different neuronal cell types and the evolutionary significance of
SPAST targeting by each of these miRNAs. In addition, miR-1271
has an identical seed sequence as miR-96 and can function in
similar neural pathways [74]. Future studies will determine
whether miR-1271 has a role in SPAST regulation.
Implications for Diagnostics and Therapeutics in
Neurodegenerative Disease
Identification in this study of evolutionarily conserved, func-
tional motifs in the SPAST promoter as cis-binding sites for NRF1
and SOX11 has important implications for molecular diagnostic
studies in HSP. We propose that mutations in these key cis-
regulatory elements would reduce spastin levels below a physio-
logical threshold required for axonal function, and hence result in
a HSP phenotype. Mutations in TF binding sites in the SPAST
promoter could occur in either familial HSP or in sporadic spastic
paraplegia cases. This mechanism would be consistent with
haploinsufficiency as a pathogenic mechanism and, indeed, only
slight changes in spastin levels are sufficient to alter neurite
stability and growth [25]. NRF1 binding is sensitive to DNA
methylation [38,42,75], and abnormal epigenetic modifications in
the SPAST promoter could also perturb SPAST expression and
contribute to pathogenesis in HSP.
The miRNA regulation of SPAST also has implications for
mutation studies in neurodegenerative disease. Mutations in
miRNA binding sites that prevent pairing between the miRNA
and target may upregulate SPAST mRNA and protein levels.
Given that increases in SPAST levels result in neurite phenotypes
in a dose-sensitive manner ranging from beneficial to toxic
changes [25], dysregulation of SPAST levels due to abnormal
miRNA dynamics may contribute to pathogenesis of neurological
phenotypes.
An understanding of the transcriptional and post-transcriptional
regulatory mechanisms controlling expression of SPAST and for
other HSP loci will determine whether HSP genes are co-
regulated in normal neuronal development and aging, and in
neurodegenerative conditions such as HSP. These mechanisms
may also be relevant to other neurodegenerative conditions, since
recent studies have shown that the mRNA levels of several spastic
paraplegia gene loci including spastin (spg4), spg7, and spg20, are
down-regulated in purified brain neurons from patients with
multiple sclerosis (MS), an autoimmune disorder [76]. Indeed,
these findings may explain the similar clinical phenotype that
occurs with progression of MS, including spastic paraparesis with
neurodegeneration in the corticospinal tracts and posterior
columns [76].
Knowledge of regulatory mechanisms for spastin synthesis may
have therapeutic implications, albeit speculative. As a dominant
genetic disorder, SPG4 is dosage-sensitive and thus upregulation of
the normal SPAST allele could provide therapeutic benefits by
preventing or delaying neurodegeneration. For example, NRF1 is
positively regulated by AMP-activated protein kinase (AMPK),
a cellular energy sensor [77–78]. Increased levels or activity of
AMPK can be induced by exercise and caloric restriction [79] or
with metformin [79–80], b-GPA (b-guanadinopropionic acid)
[77], resveratol [79,81], the AMP memetic AICAR (5-aminoimi-
dazole-4-carboxamide ribonucleoside) [81], or novel pharmaco-
logical drugs [79,82]. Indeed, resveratol activates AMPK in
neurons and in conjunction with AICAR induces neurite
outgrowth [81], and several of these drugs are in use for metabolic
syndrome [79] and heart disease [80]. Alternatively, or in
combination, targeted knockdown of key miRNA levels in motor
cortex neurons could increase spastin expression. These regulatory
mechanisms involved in spastin production could also be targeted
for cell-based screening to identify small molecule agonists or
antagonists, respectively. Treatment by one or more of these
approaches could potentially increase NRF1-mediated activation
of SPAST in association with a haploinsufficient mutation,
although success may require that the level of mutant SPAST
mRNA remain low by nonsense-mediated mRNA decay or
proteosomal degradation of unfolded, unstable, or misrouted
proteins. These novel ideas for future therapeutic targeting for
patients having SPG4 due to haploinsufficient mutations in
SPAST, and potentially for other neurodegenerative diseases such
as MS with downregulation of spastin function, can be tested in
animal models [59,64,68,73,83–84] and if and when warranted
subsequently in clinical trials.
Materials and Methods
Bioinformatics
To identify potential TF binding motifs 59 of SPAST exon 1, we
used human SPAST genomic sequence and screened for
evolutionary conservation among sequenced mammalian genomes
[34]. BLAST analyses for sequence similarity (http://blast.ncbi.
nlm.nih.gov/Blast.cgi) utilized standard parameters for searches of
the non-redundant (NR), high throughput genome sequence
(HTGS), and whole genome shotgun (WGS) databases. All
extended 59 sequences spanning the SPAST promoter from 21
mammalian genomes are provided in Dataset S1. For analysis of
the Alu insertion in the SPAST 39-UTR, we also used BLAST
analysis of primate genomes in the Trace Archives WGS database.
When necessary, due to low overall sequence similarity, mamma-
lian and non-mammalian genome sequences for the SPAST
promoter and 39-UTR were obtained from the Ensembl genome
browser (http://www.ensembl.org/index.html). To identify po-
tential miRNA binding sites in the 39-UTR of the SPAST mRNA,
miRNA predictions used TargetScan 5.2 (http://www.targetscan.
org/), which is one of two programs shown to most accurately
predict in vivo miRNA targeting sequences [45], while miRNA
sequences are from miRBase (http://www.mirbase.org/). For
promoter and 39-UTR multi-sequence alignments, we used
ClustalW 2.1 (http://www.ebi.ac.uk/Tools/clustalw2/index.
html). To generate a consensus primate phylogenetic tree for the
10 species of interest, we used version 3 of the 10kTrees website
(http://10ktrees.fas.harvard.edu/) [85].
Cell Culture
A human neuronal precursor cell line derived from embryonic
kidney [86], Flp-In-293 (Invitrogen, Carlsbad, CA), was passaged
in Dulbecco’s Modified Eagle Media (DMEM) supplemented with
fetal bovine serum (FBS), L-Glutamine, penicillin, streptomycin,
and Zeocine (Invitrogen), following the manufacturer’s sugges-
tions. The human neuroblastoma cell line, SK-N-SH (provided by
Dr. Nina F. Schor, University of Rochester, Rochester, NY), was
passaged in Eagle’s Minimum Essential Media (EMEM) supple-
mented with FBS, L-Glutamine, penicillin, and streptomycin. The
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murine neuroblastoma cell line, Neuro2a (provided by Dr. Nina F.
Schor, University of Rochester), was passaged in EMEM
supplemented with FBS, L-Glutamine, penicillin, streptomycin,
and non-essential amino acids.
Chromatin Immunoprecipitation (ChIP)
Approximately 16106 cells were plated on 35 cm2 plates, and at
70–80% confluency, formaldehyde was added to the media at
a final concentration of 1%, and the plates were incubated at
37uC, 10 min to crosslink protein to DNA. Cells were washed
twice with 5 ml ice-cold PBS, scraped from the plates using a cell
lifter, centrifuged, re-suspended in SDS lysis buffer (ChIP assay kit;
Millipore, Billerica, MA), and sonicated to shear DNA. An aliquot
of this DNA was taken as a Total Input control. Samples were
precleared with protein G-agarose/salmon sperm beads (Milli-
pore), protein-DNA complexes were immunoprecipitated with
anti-NRF1 [42], and a no antibody control was similarly
processed. Complexes were collected with Protein G agarose/
salmon sperm beads and washed, protein-DNA complexes eluted
off the beads, and crosslinks were reversed by incubation in NaCl
for 16 hr at 65uC. DNA was recovered by phenol-chloroform
extraction, precipitated by ethanol, and PCR performed using
primers in Table S2.
Expression of siRNA Targeting NRF1 mRNA
SK-N-SH cells were sub-cultured on 75 cm2 flasks for 24 hr prior
to nucleofection, and at 80–90% confluence, 4 mg of pSUPER-
NRF1 DNA [42,87] were transfected into 16106 cells using an
Amaxa nucleofector II device (Lonza, Walkerville, MD). The
transfected cells were plated on a 6-well plate, and 24 hr later RNA
was extracted with Trizol, treated with DNase I to remove genomic
DNA contaminants, and 1 mg of RNA from each sample was reverse
transcribed into cDNA using SuperScript III reverse transcriptase
(Invitrogen) according to the manufacturer’s instruction. PCR was
performed using gene-specific primers (Table S2) to examine gene
expression, withGAPDH as a negative control andNRF1 as a positive
control to ensure effective down regulation by siRNA.
Co-transfections with siRNA and Luciferase Reporter
Constructs
The evolutionarily conserved segment of the SPAST promoter
from -197 to+107 with respect to the SPAST 5-TSS (Fig. 1A) was
isolated by PCR using primers in Table S1, and subcloned into
the pGL3-enhancer (pGL3e) luciferase vector (Promega, Madison,
WI). This pGL3e-SPAST-promoter construct was co-transfected
into SK-N-SH cells with a shRNA vector targeting NRF1
(pSUPER-NRF1), or as controls, shRNA vectors targeting
luciferase mRNA (pSUPER-luc) or an unrelated gene (pSUPER-
Arl2) [42], and luciferase reporter assays were performed.
Transcription Factor and miRNA Transfections
For all transfections, cells were seeded in antibiotic-free media
the night before transfection. Transfections were carried out in
Opti-MEM I (Invitrogen) with Lipofectamine 2000 (Invitrogen)
(diluted 1:100) for 16 hr. For luciferase assays, we seeded 86104
cells into 24 well plates, and co-transfected Flp-In-293 cells with
1 mg/ml of pGL3b-derived vectors (containing a firefly luciferase
gene; Promega) and 25 ng/ml of pRL-SV40 vector (containing
a Renilla luciferase gene, Promega). To increase cellular levels of
miR-96, miR-182, and miR-367, we seeded 76105 Flp-In-293
cells into 25 cm2 tissue culture flasks and transfected them with
Pre-miR miR-96, Pre-miR miR-182, Pre-miR miR-367, or Pre-
miR Negative Control 1 (Ambion, Austin, TX) at a concentration
of a 100 nM. To increase NRF1 and SOX11 levels, Flp-In-293
cells were transfected with 250 ng/ml of pNRF1-VP16 [44] and
pCMV-SOX11 [43], respectively. As a negative control for the
latter TF experiments, we also transfected Flp-In-293 cells with
250 ng/ml of a non-specific control plasmid (pGL3-basic). All
transfections were performed in triplicate.
Luciferase Reporter Assays
For luciferase assays, we fused various portions of the human
SPAST promoter to the luciferase gene in pGL3b (Promega). The
pGL3b-SPAST-promoter construct used the same evolutionarily
conserved promoter segment as for pGL3e-SPAST-promoter,
described above. To remove the 59 NRF1-like sequence and
a Sp1 motif (see Fig. 1A,B; Fig. 5A,B), we digested pGL3b-
SPAST-promoter with MluI and religated the vector, creating
pGL3b-SPAST-promoter-no-Sp1. To remove the SOX11 binding
motif, we digested pGL3b-SPAST-promoter-no-Sp1 with BssHII
and MluI and religated the plasmid, creating pGL3b-SPAST-
promoter-no-Sp1-no-SOX11. In addition, we generated two
additional reporter vectors that have a PCR-isolated 182-bp
segment (from -379 to -198, with respect to the 59-TSS) located
immediately upstream of the 304-bp SPAST promoter segment, to
assess activity associated with a putative Elk1 binding site [32] at
position -230 to -222 from the 59-TSS. The 182-bp segment was
subcloned by itself in pGL3b as well as upstream of the full-length
SPAST promoter in pGL3b-SPAST-promoter (see Fig. S2, left).
The SPAST-promoter-luciferase derivatives were co-transfected
into Flp-In-293 cells with the pRL-SV40 vector containing a Renilla
luciferase gene, for normalization purposes, and for some
experiments, we included pCMV-SOX11. 16 hr after transfection
the cells were lysed and luciferase activity was measured using
Dual-luciferase reporter assay (Promega) on a Luminometer 20/
20n (Turner BioSystems, Sunnyvale, CA). For each sample, the
firefly luciferase activity was normalized to Renilla luciferase
activity, and the relative luciferase activity was normalized to the
luciferase activity of cells transfected with pGL3b vector. Each
experimental group was done in three biological replicates, and
the data were analyzed using a two-tailed t-test.
Quantitative Gene Expression Analysis
RNA was isolated using the miRNeasy miRNA isolation kit
(Qiagen, Valencia, CA). Reverse transcription reactions were
performed using the SuperScript III First-Strand Synthesis System
for RT-PCR (Invitrogen), following the manufacturer’s sugges-
tions. Quantitative RT-PCR (qRT-PCR) was done on the Applied
Biosystems 7300 Real-Time PCR System (Applied Biosystems,
Carlsbad, CA) using SYBR Green Master Mix (Applied
Biosystems). Primers used for PCR amplification are listed in
Table S2. Each experimental group was done in three biological
replicates, each of which were repeated in three technical
replicates, and each qRT-PCR plate included no reverse
transcriptase and no template controls. The data were analyzed
using the comparative CT method [88]. To examine statistical
significance of the data, we analyzed the average of the biological
replicates with ANOVA analysis.
Protein Studies by Western Blot Analysis
Cells were washed with cold PBS and lysed (on ice) with
a solution containing 50 mM Tris, 1% Triton X-100, 150 mM
NaCl, 1 mM DTT, 10 mg/ml leupeptin, 0.1% sodium dodecyl
sulfate, 10 mg/ml pepstatin, and 1 nM phenyl methyl sulfonyl
fluoride. Protein concentrations were established using the Bio-
Rad Quick Start Bradford Protein Assay Kit (Bio-Rad Laborato-
ries, Hercules, CA). Normalized cell lysates were resolved by
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sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE). Proteins were transferred to Immobilon-P membranes
(Millipore). Membranes were hybridized with an anti-spastin
primary antibody (sc-53443; Santa Cruz Biotechnology, Santa
Cruz, CA) for 2–4 hr at room temperature. To verify equal
protein loading, membranes were stripped with Restore Western
Blot Stripping Buffer (Thermo Scientific, Waltham, MA) and
probed for GAPDH (Sigma-Aldrich, St. Louis, MO). Membranes
were incubated with the corresponding secondary antibody for
1.5 hr at room temperature. Proteins were visualized using the
Western Blotting Luminol Reagent (Santa Cruz Biotechnology).
Densitometric analyses were carried out using NIH ImageJ
software (http://rsbweb.nih.gov/ij/).
Supporting Information
Dataset S1 SPAST promoter-exon 1 sequences from
twenty eutherian mammalian and one marsupial spe-
cies that were used for multisequence alignments in this
study. Symbols are: bold red, consensus motif for NRF1 binding
sites; bold green/yellow shade, consensus motif for SOX11
binding site; bold purple, consensus motif for Sp1 binding sites;
bold pink, motifs proposed for Elk1 binding sites (see Canbaz et al.
2011), although these are poorly conserved (see Fig. S1); bold red
and underlined, initiation codon for translation of the 68 kDa
spastin isoform; underlined 20–22 nucleotide sequences (human
and mouse), ChIP PCR primers; gray shade (human sequence),
upstream transcription start site (TSS).
(PDF)
Figure S1 Evolutionary conservation of the SPAST pro-
moter in mammals identifies transcription factor (TF)
binding sites. A) Multisequence alignment for 19 eutherian
mammalian species of the full-length SPAST promoter region into
exon 1 and including the translational start codon (a segment of
474-nt in human). In addition, Spast promoter-exon 1 sequence
alignments are shown for B) tenrec and elephant, and C) western
European hedgehog and a marsupial, Monodelphis domestica (the
tenrec and hedgehog sequences are also shown in A). Despite
a high degree of nucleotide conservation, elephant is the only
sequenced mammalian genome in which the SOX11 site has been
lost and replaced by duplications of NRF1 binding site elements
(shown by gray shading). Sequences were aligned using ClustalW
2.1 and manually adjusted as needed for maximum parsimony.
The TF binding sites identified in this study are indicated in bold
type (red, NRF1; green, SOX11; purple, Sp1); a poorly conserved
putative site for Elk1 (Canbaz et al. 2011) is also shown (pink);
yellow shading, highly conserved SOX11 binding site; INIT,
translation start site for spastin; *, nucleotide positions conserved
in all aligned sequences;ˆ, nucleotide positions conserved in 90%
(17 of 19) of aligned sequences.
(PDF)
Figure S2 An extended region upstream of the SPAST
promoter that includes a putative Elk1 binding site, has
minor effects on transcriptional activity. A fragment
containing the putative Elk1 site (Canbaz et al. 2011) was ligated
into the pGL3b vector to generate pGL3b-Elk1 and into the
pGL3b-SPAST-promoter construct (the ‘‘full-length promoter’’
construct in Fig. 5A) to generate pGL3b-SPAST-promoter-Elk1,
which are depicted in the panel on the left. Luciferase assays were
performed and the data was normalized to the pGL3b vector, as
presented in the panel on the right. Inclusion of the fragment with
the Elk1 site led to a significant increase (9-fold) in luciferase
activity in pGL3b-Elk1 as compared to pGL3b, but this is
significantly less than that from the ‘‘full-length promoter’’
construct with 71-fold increased activity over pGL3b. Inclusion
of the fragment with the Elk1 site into the pGL3b-SPAST-
promoter construct led to a slight decrease in luciferase activity
that was not significantly different than luciferase activity in cells
transfected with pGL3b-SPAST-promoter.
(PDF)
Figure S3 Evolutionary establishment and maintenance
ofmiR-367 targeting of SPASTmRNA in primates. A)Base-
pairing of theHomo sapiens (hsa) miR-367 miRNA with the SPAST 39-
UTR. The optimal seed motif (green text and yellow shade) for
targeting by the miRNA is at position 1,594–1,600 of the SPAST 39-
UTRforhuman,andsimilarly theoptimal seedmotif ismaintained in
chimpanzee, orangutan, and gibbon (seeFig.S3C). In macaque and
baboon, the SPAST target:miR-367 seed pairing includes a U:G pair
(see Fig. S3C). Additional sequences that can contribute to the
SPAST target:miR-367 pairing outside the seed are shown by gray
shade.B)ThemiRNAseed motif formiR-367 is sharedwith six other
miRNAs, any of which could target theSPAST39-UTR in vivo. At top,
the human SPAST 39-UTR sequence that is targeted by miR-367 is
displayed, followed underneath by the 7 mature miRNA sequences
(from miRBase) that wouldbe capable of targeting theSPASTmRNA
(yellow shade, miRNA seed and target sequences; gray shade,
nucleotides that can contribute to auxiliary pairing, without gaps).C)
Multisequence alignment in primate species for the boundaries of the
Alu element insertion in the SPAST 39-UTR, highlighting the 18-nt
target site duplication (TSD; bold blue and underline) and the miR-
367 target site (yellow shade, target sequence for optimal miR-367
seed; gray shade, auxiliary pairing). D) Multisequence alignment in
mammals for the position of the Alu element insertion in the SPAST
39-UTR, highlighting the 18-nt TSD present in catarrhine primates
and single copy in the other mammalian species. In C) and D): *,
conserved in all species;ˆ , conserved in 13/14 species;+, presence of
the Alu element insertion; - (in species name), absence of the Alu
element insertion;##Alu## represents the remaining Alu element
sequences, not shown for illustrative purposes; Tn represents the
number of T nucleotides at that position. E) Primate phylogenetic
tree showing the presence (+) or absence (-) of an Alu repetitive
element insertion in the SPASTIN 39-UTR, that includes a miR-367
optimal seed motif for targeting by the miRNA. An * indicates species
in which the pairing of miR-367 with its target includes a G:U pair.
The putative origin of the Alu element is shown by a red arrow.
(PDF)
Table S1 Conservation of SPAST 39-UTR motifs as
‘‘optimal seeds’’ for miRNA targeting.
(PDF)
Table S2 PCR primers used in this study.
(PDF)
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